Sangamo Biosciences, Inc.  

(Public, NASDAQ:SGMO)   Watch this stock  
Find more results for SGMO
5.51
-0.41 (-6.93%)
Jun 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.45 - 5.75
52 week 4.63 - 12.48
Open 5.57
Vol / Avg. 1.12M/828,522.00
Mkt cap 361.51M
P/E     -
Div/yield     -
EPS -0.74
Shares 70.49M
Beta 2.28
Inst. own 70%
Aug 3, 2016
Q2 2016 Sangamo BioSciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 21, 2016
Sangamo BioSciences Inc Annual Shareholders Meeting (Estimated)
Jun 14, 2016
Sangamo BioSciences Inc Annual Shareholders Meeting
Jun 8, 2016
Sangamo BioSciences Inc at Jefferies Healthcare Conference
Jun 1, 2016
Sangamo BioSciences Inc Conference Call to Discuss Appointment of New President & CEO - Webcast
May 19, 2016
Sangamo BioSciences Inc at Terrapinn Holdings World Stem Cells & Regenerative Medicine Congress
May 17, 2016
Sangamo BioSciences Inc at Piper Jaffray GenomeRX Symposium
May 5, 2016
Sangamo BioSciences Inc at Deutsche Bank Health Care Conference
May 2, 2016
Q1 2016 Sangamo BioSciences Inc Earnings Call
May 2, 2016
Q1 2016 Sangamo BioSciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -418.42% -102.94%
Operating margin -423.16% -118.51%
EBITD margin - -116.01%
Return on average assets -31.94% -17.68%
Return on average equity -35.58% -20.40%
Employees 119 -
CDP Score - -

Address

501 Canal Blvd
RICHMOND, CA 94804-3559
United States - Map
+1-510-9706000 (Phone)
+1-510-2368951 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics. Its ZFP Therapeutic, SB-728, a ZFP nuclease (ZFN)-modified autologous cell product for the treatment of Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS), is the therapeutic application of its ZFN genome editing technology and is evaluated in an ongoing Phase II study of ZFN-modified T-cells (SB-728-T-1101, Cohort 3) and a Phase I/II study of modified hematopoietic stem cells (SB-728mR-HSPC) in HIV-infected subjects. It has preclinical programs in hemophilia A and Lysergic acid diethylamide and research stage programs in monogenic diseases, including certain central nervous system disorders and cancer immunotherapy.

Officers and directors

Alexander Macrae President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
H. Ward Wolff Chief Financial Officer, Principal Financial and Accounting Officer, Executive Vice President
Age: 67
Bio & Compensation  - Reuters
Geoffrey M. Nichol Executive Vice President - Research and Development
Age: 59
Bio & Compensation  - Reuters
Dale G. Ando M.D. Vice President - Therapeutic Development, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Edward O. Lanphier II Non-Executive Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
H. Stewart Parker Director
Age: 59
Bio & Compensation  - Reuters
William R. Ringo Jr. Director
Age: 69
Bio & Compensation  - Reuters
Paul B. Cleveland Independent Director
Age: 59
Bio & Compensation  - Reuters
Stephen G. Dilly Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters